


Abstract LSO-062 Figure 1 Mean SLEDAI-2k at baseline, 3, 6 and 12 months, in A) Rituximab (n=1089), B) Belimumab (n=179) and C) SoC (n=208) treated patients

Conclusions Although absolute reduction in disease activity was similar across ethnic backgrounds, obtaining a MCR following treatment was lower in Black and Indo-Asian patients, in part reflecting higher baseline disease activity, but not explained by level of social deprivation; an observation not confined to a single treatment. There is a need for investigation into the drivers of these inequitable outcomes and reappraisal of treat-to-target strategies in these populations.

LSO-104 IMPACT OF TIME TO REMISSION, FLARES AND EXPOSURE TO IMMUNOSUPPRESSIVES ON THE DEVELOPMENT OF ADVANCED CHRONIC KIDNEY DISEASE (STAGE IV OR WORSE) IN LUPUS NEPHRITIS

¹Konstantinos Tselios, ²Dafna Gladman*, ²Jiandong Su, ²Murray Urowitz. ¹Division of Rheumatology, Department of Medicine, McMaster University, Canada; ²Centre for Prognosis Studies in Rheumatic Diseases, Toronto Lupus Clinic, University Health Network, University of Toronto, Canada

10.1136/lupus-2023-KCR.105



Abstract LSO-104 Figure 1 Kaplan-Meier curve for the outcome of advanced CKD according to the time to complete remission